Literature DB >> 11574413

Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator-activated receptor-gamma-mediated changes in gene expression.

B Brunmair1, F Gras, S Neschen, M Roden, L Wagner, W Waldhäusl, C Fürnsinn.   

Abstract

Thiazolidinediones (TZDs) are believed to induce insulin sensitization by modulating gene expression via agonistic stimulation of the nuclear peroxisome proliferator-activated receptor-gamma (PPAR-gamma). We have shown earlier that the TZD troglitazone inhibits mitochondrial fuel oxidation in isolated rat skeletal muscle. In the present study, rat soleus muscle strips were exposed to TZDs to examine whether the inhibition of fuel oxidation is mediated by PPAR-gamma activation. Our findings consistently indicated direct, acute, and PPAR-gamma-independent TZD action on skeletal muscle fuel metabolism. Rapid stimulation of lactate release by 20 micromol/l troglitazone within 30 min suggested that direct TZD action on skeletal muscle in vitro does not rely on changes in gene expression rates (12.6 +/- 0.6 [control] vs. 16.0 +/- 0.8 micromol. g(-1). h(-1) [troglitazone]; P < 0.01). This conclusion was supported by the failure of actinomycin D and cycloheximide to block the effects of troglitazone. Mitochondrial fuel oxidation was consistently inhibited by six different TZDs (percent inhibition of CO(2) production from palmitate after 25 h: troglitazone, -61 +/- 2%; pioglitazone, -43 +/- 7%; rosiglitazone, -22 +/- 6%; BM13.1258, -47 +/- 9%; BM15.2054, -51 +/- 4%; and T-174, -59 +/- 4% [P < 0.005 each]), but not by PPAR-gamma agonistic compounds not belonging to the TZD class (JTT-501, -5 +/- 7% [NS]; prostaglandin J(2), 17 +/- 7% [P < 0.05]), which further argues against dependence on PPAR-gamma activation. In summary, our findings provided good evidence that direct inhibition of mitochondrial fuel oxidation in isolated skeletal muscle is a group-specific effect of TZDs and is independent of PPAR-gamma-mediated gene expression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11574413     DOI: 10.2337/diabetes.50.10.2309

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  22 in total

Review 1.  Peroxisome proliferator-activated receptors: lipid binding proteins controling gene expression.

Authors:  Marc van Bilsen; Ger J van der Vusse; Andries J Gilde; Martijn Lindhout; Karin A J M van der Lee
Journal:  Mol Cell Biochem       Date:  2002-10       Impact factor: 3.396

Review 2.  Peroxisome proliferator activated receptors, fatty acids and muscle insulin resistance.

Authors:  Edward Kraegen; Gregory Cooney; Ji-Ming Ye; Stuart Furler
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

3.  Thiazolidinediones inhibit proliferation of microvascular and macrovascular cells by a PPARgamma-independent mechanism.

Authors:  M Artwohl; C Fürnsinn; W Waldhäusl; T Hölzenbein; G Rainer; A Freudenthaler; M Roden; S M Baumgartner-Parzer
Journal:  Diabetologia       Date:  2005-02-24       Impact factor: 10.122

4.  Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.

Authors:  Shanming Hu; Jianrong Yao; Alexander A Howe; Brandon M Menke; William I Sivitz; Arthur A Spector; Andrew W Norris
Journal:  Mol Endocrinol       Date:  2012-04-03

5.  Differences in troglitazone action on glucose metabolism in freshly isolated vs long-term incubated rat skeletal muscle.

Authors:  Florian Gras; Barbara Brunmair; Michael Roden; Werner Waldhäusl; Clemens Fürnsinn
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

Review 6.  PPARgamma1 and LXRalpha face a new regulator of macrophage cholesterol homeostasis and inflammatory responsiveness, AEBP1.

Authors:  Amin Majdalawieh; Hyo-Sung Ro
Journal:  Nucl Recept Signal       Date:  2010-04-16

7.  Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma.

Authors:  Charles W Bolten; Patrick M Blanner; William G McDonald; Nicholas R Staten; Richard A Mazzarella; Graciela B Arhancet; Martin F Meier; David J Weiss; Patrick M Sullivan; Alexander E Hromockyj; Rolf F Kletzien; Jerry R Colca
Journal:  Gene Regul Syst Bio       Date:  2007-09-17

Review 8.  Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Authors:  Antona J Wagstaff; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Peroxisome proliferator-activated receptor-gamma agonist improves skeletal muscle insulin signaling in the pregestational intrauterine growth-restricted rat offspring.

Authors:  Shilpa Oak; Cang Tran; Maria-Olivia Castillo; Shanthie Thamotharan; Manikkavasagar Thamotharan; Sherin U Devaskar
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-02       Impact factor: 4.310

10.  Apolipoprotein AII is a regulator of very low density lipoprotein metabolism and insulin resistance.

Authors:  Lawrence W Castellani; Cara N Nguyen; Sarada Charugundla; Michael M Weinstein; Chau X Doan; William S Blaner; Nuttaporn Wongsiriroj; Aldons J Lusis
Journal:  J Biol Chem       Date:  2007-12-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.